BACKGROUND The treatment of coronary artery disease involving distal segments remains a challenge. Differently from metallic platform stents (MPS), bioresorbable vascular scaffolds (BVS) may potentially provide expansive remodeling, the return of vessel vasomotion and permit surgical revascularization. Notwithstanding, data at late follow-up in this setting are scant.
BACKGROUND The treatment of coronary artery disease involving distal segments remains a challenge. Differently from metallic platform stents (MPS), bioresorbable vascular scaffolds (BVS) may potentially provide expansive remodeling, the return of vessel vasomotion and permit surgical revascularization. Notwithstanding, data at late follow-up in this setting are scant.
METHODS The Italian RAI Registry is an ongoing, spontaneous, multicenter prospective data collection which evaluates all patients treated at participating centres with the second-generation everolimus-eluting Absorb BVS. Our analysis was restricted to patients who received Absorb BVS implantation in at least one distal segment of an epicardial coronary artery.
RESULTS Between March 2012 and June 2015, 1089 consecutive unselected patients were treated by BVS. 121 patients (mean age 59 years, 86% males) were included in this analysis. A total of 135 lesions involving distal segments were treated with Absorb BVS in this cohort. Seventy-six (63%) patients had an acute coronary syndrome. Diabetic patients were 29 (24%). Multivessel coronary artery disease was present in 69% of patients, and the median SYNTAX score was 17 AE 12. Multivessel implantation occured in 40 (33%) patients and 21% of patients received metallic stents proximally. The total number of BVS implanted was 269, with an average of 2.2/patient. Final scaffold length was !28 mm in the majority of patients (52%) with 79 overlaps. Procedural success occurred in 96% of patients. At a median follow up of 25 months (interquartile range, 12 -37 months), target lesion failure rate was 5.8%. More in detail, adverse events were: 1 cardiac death, 5 target vessel myocardial infarctions, 4 target lesion revascularizations because of definite scaffold thrombosis (3 sub-acute, 1 very late).
CONCLUSIONS By the data of the RAI registry, the implantation of Absorb BVS in distal segments is promising. Randomized studies are needed to assess the potential benefit of BVS to treat distal coronary lesions compared to MPS or incomplete revascularization. BACKGROUND Percutaneous coronary intervention (PCI) with bioresorbable vascular scaffold (BVS) placement holds great potential, but concern has recently been raised regarding the risk of scaffold thrombosis (ST). The aim of this study was to determine the risk of ST following PCI with placement of an ABSORB BVS by conducting a systematic review and meta-analysis.
METHODS Medline/PubMed, Cochrane CENTRAL, and meeting abstracts were searched for all studies that included outcomes data in patient following PCI with BVS placement. For studies comparing BVS with drug-eluting stents (DES), pooled estimates of outcomes, presented as odds ratios (OR) [95% confidence intervals], were generated with random-effect models.
RESULTS Our analysis included 10,021 patients (8,303 with BVS and 1,718 with DES) with a follow-up of 6.4AE5.1 months, age of 60AE11, 78% were male, 38% had stable angina, and 56% had ACS. CV death occurred in 0.6% of patients with BVS, MI in 2.1%, target lesion revascularization in 2.0%, and definite/probable ST in 1.2% of patients. Among BVS patients, 0.3% had acute ST and 0.6% had subacute ST, yielding a risk of 0.9% for ST in the first month. Meta-analysis demonstrated patients that received BVS were at a higher risk of MI ], p¼0.004) and definite/probable ST (OR 2.14 [1.02-4.50], p<0.05) during follow-up (Figure) .
CONCLUSIONS Patients undergoing PCI with BVS had increased definite/probable ST and MI during follow-up compared with DES. Measures to minimize scaffold thrombosis are warranted. Further randomized controlled trials with the long-term follow-up will determine the overall utility of BVS compared to DES implantation in high-risk patient subgroups.
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Impact of postdilation on procedural and clinical outcomes in long and complex lesions treated with bioresorbable vascular scaffolds-a prospective registry study BACKGROUND There is limited data on the impact of postdilation (PD) on acute procedural and clinical outcomes in patients with long and complex lesions treated with bioresorbable vascular scaffolds. We sought to evaluate the effect of PD on procedural and clinical outcomes in a 'real world' population.
METHODS We performed an analysis of patients who underwent BRS implantation and enrolled into our institutional BVS STEMI FIRST and EXPAND registries. Pre and post dilation were encouraged with at least 1:1 preballoon: artery (B: A) and postballoon: scaffold (B: S) ratios respectively. Baseline clinical and angiographic (including quantitative coronary angiographic analysis; QCA) characteristics were collected. The effect of PD on angiographic outcome were also evaluated using appropriate views taken immediately after BRS implantation (before postdilation) and final procedure when available. Patients were followed up routinely through telephone call and hospital visits. Procedural end points studied included device and procedure success and complication rates. Major adverse cardiovascular events (MACE) studied included all-cause mortality, myocardial infarct, target lesion revascularization and scaffold thrombosis.
RESULTS 294 patients with 387 lesions treated with 529 BRS were studied of which 164 patients with 211 lesions underwent PD (Post B:S: 
